Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2187873 | 0.88 | TRPM8 (0.47) | HPGDHSD17B10KDM4ETDP1SMN1; SMN2 | |
| SCHEMBL2185859 | 0.85 | KDM4E (0.44) | HPGDHSD17B10KDM4EALDH1A1HIF1A | |
| SCHEMBL7867003 | 0.79 | KDM4E (0.42) | KDM4EALDH1A1HIF1ATDP1RAF1 | |
| SCHEMBL2755875 | 0.78 | HIF1A (0.59) | KDM4EALDH1A1HIF1ATDP1SMN1; SMN2 | |
| SCHEMBL7864555 | 0.78 | KDM4E (0.45) | HSD17B10KDM4EALDH1A1HIF1ATDP1 | |
| SCHEMBL2187950 | 0.77 | LMNA (0.44) | HPGDSMN1; SMN2HTTTSHR | |
| SCHEMBL1677429 | 0.77 | ALOX12 (0.41) | HPGDHSD17B10KDM4EALDH1A1RAF1 | |
| SCHEMBL2187683 | 0.77 | LMNA (0.31) | HIF1ATSHR | |
| SCHEMBL7864548 | 0.77 | HCRTR1 (0.42) | KDM4EALDH1A1HIF1ATDP1 | |
| SCHEMBL2186737 | 0.76 | TRPM8 (0.52) | KDM4EALDH1A1TDP1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | GIVAUDAN SA (CH) | 2011-08-18 | — | — | US | claimed |
| EP-2342180-A2 | ORGANIC COMPOUNDS SUITABLE FOR MODULATING FRAGRANCE COMPOSITIONS | Givaudan SA (CH) | 2011-07-13 | — | — | EP | claimed |
| WO-2010037244-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-04-08 | — | — | WO | claimed |
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | GIVAUDAN SA (CH) | 2011-08-18 | — | — | US | disclosed |
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | GIVAUDAN SA (CH) | 2011-08-18 | — | — | US | disclosed |
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | GIVAUDAN SA (CH) | 2011-08-18 | — | — | US | disclosed |
| EP-2342180-A2 | ORGANIC COMPOUNDS SUITABLE FOR MODULATING FRAGRANCE COMPOSITIONS | Givaudan SA (CH) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010037244-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | CYP2A6, CYP2B6, CYP2A13 | HPGD 116/4885HSD17B10 126/4885KDM4E 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.